Genetically modified cell line for production of Marek's disease virus vaccine and methods of making and using the same
The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.
1. A genetically modified avian cell line capable of supporting high-titer growth of a Marek's Disease Virus (MDV), wherein the genetic modification comprises a genetic alteration of one or more of the following genes: SLAMF8, HTR2A, STAT4, CTSL2, and COBLL1; and wherein high-titer growth refers to at least a 2-fold higher yield in the viral titer as that achieved with the same MDV strain in a parent avian cell line.
2. The genetically modified cell line of claim 1 , wherein said Marek's Disease Virus is selected from the group consisting of Marek's Disease Virus Serotype 1; Marek's Disease Virus Serotype 2; and Marek's Disease Virus Serotype 3.
3. The genetically modified cell line of claim 1 , wherein said Marek's Disease Virus is a recombinant virus.
4. The genetically modified cell line of claim 3 , wherein said recombinant Marek's Disease Virus comprises one or more heterologous antigens inserted into one or more locations in the MDV genome.
5. The genetically modified cell line of claim 4 , wherein said one or more heterologous antigens comprise antigens from pathogenic avian viruses.
6. The genetically modified cell line of claim 5 , wherein said pathogenic avian viruses are selected from the group consisting of: Infectious Bursal Disease Virus; Infectious Bronchitis Virus; Infectious Laryngotracheitis Virus; Newcastle Disease Virus; Chicken Anemia Virus and Avian Influenza Virus.
7. A method of producing a genetically modified cell line capable of supporting high-titer growth of Marek's Disease Virus (MDV), the method comprising: providing a starting cell line, wherein said starting cell line is an immortalized avian cell line, and producing a genetically modified cell line by genetically altering the starting cell line to reduce expression thereby altering functional activity of the product of one or both of gene HTR2A and SLAMF8, wherein the genetically modified cell line is capable of supporting increased MDV viral titer as compared to the starting cell line when infected with the same MDV strain.
8. The method of claim 7 , wherein said starting cell line is selected from the group consisting of: JBJ-1, DF-1; LF-1; LMH; SL-29; DT-40; ESCDL-1; SC-1; SC-2; and ST-2.
9. The method of claim 8 , wherein said starting cell line comprises JBJ-1.
10. The method of claim 7 , wherein the genetic alteration comprises altering the genome using TALENs, ZFNs, CRISPR-Cas9, or alternative CRISPR-Cas enzymes.
11. The method of claim 10 , wherein the genetic alteration comprises altering the genome using CRISPR-Cas9.
12. The method of claim 7 , wherein the genetically modified cell line supports an MDV viral titer at least 10-fold higher than the starting cell line when infected with the same MDV strain.
13. The method of claim 7 , wherein the genetically modified cell line supports an MDV viral titer at least 50-fold higher than the starting cell line when infected with the same MDV strain.
14. The method of claim 7 , wherein the genetically modified cell line supports an MDV viral titer that is within 2-fold of the viral titer achieved with the same MDV strain on primary chicken embryo fibroblast (CEF) cells.
15. The method of claim 7 , wherein the genetically modified cell line comprises a genetic alteration that alters the functional activity of the product of the HTR2A gene.
16. The method of claim 15 , wherein the genetically modified cell line further comprises a genetic alteration that alters functional activity of the product of one or more additional genes selected from the group consisting of STAT4, COBBL2, and CTSL.
17. The method of claim 16 , wherein said additional gene comprises STAT4.
18. A genetically modified cell line capable of supporting high-titer growth of Marek's Disease Virus (MDV), produced by the method of claim 7 .
19. The genetically modified cell line of claim 18 , wherein the MDV comprises nucleic acids that encode heterologous antigens inserted into one or more locations in the MDV genome.
20. The genetically modified cell line of either claim 18 or claim 19 , wherein the heterologous antigens are from poultry pathogens selected from the group consisting of: Infectious Bursal Disease Virus; Infectious Bronchitis Virus; Newcastle Disease Virus; Infectious Laryngotracheitis Virus; Avian Influenza Virus; and Chicken Anemia Virus.
21. A method of preparing an MDV vaccine, the method comprising: preparing a genetically modified cell line by the method of claim 7 and growing said MDV in said genetically modified cell line.
22. The genetically modified cell line of claim 1 , wherein the high-titer growth refers to at least a 10-fold higher yield in the viral titer as that achieved with the same MDV strain in a parent avian cell line.
23. The genetically modified cell line of claim 1 , wherein the high-titer growth refers to at least a 50-fold higher yield in the viral titer as that achieved with the same MDV strain in a parent avian cell line.